Pharmaceuticals 4 December 2025

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics, Inc. is back in the spotlight. On December 8, 2025, the biotech stock surged roughly 20% intraday after the company released new Phase 1 data for its Bruton’s tyrosine kinase degrader bexobrutideg in blood cancers at the American Society of Hematology Annual Meeting and scheduled a corporate webcast for this evening. MarketBeat+3GlobeNewswire+3GlobeNewswire+3

8 December 2025

NASDAQ:NRIX·Pharmaceuticals·Stock Market

Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Johnson & Johnson is trading around $202–203 per share in New York trading on December 8, 2025. Recent closing data show the stock finished at $202.48 on December 8 after a modest decline of 0.27%.StockAnalysis

8 December 2025

Financial Forecasts·NYSE:JNJ·Pharmaceuticals

Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck & Co., Inc. is back in the spotlight. As of the afternoon of December 8, 2025, Merck shares trade around $98–99, down about 1% on the day and modestly below their recent 52‑week high of $105.84 reached in late November. That pullback comes after a powerful rebound from a May low near $76, driven by excitement over new cardiovascular and respiratory drugs, plus a $9.2 billion flu‑drug acquisition — even as investors remain focused on the looming 2028 patent cliff for Keytruda and fresh regulatory headwinds.Finviz+2Reuters+2

8 December 2025

NYSE:MRK·Pharmaceuticals·Stock Market

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals’ stock is back in the spotlight on 8 December 2025 after the company reported encouraging mid‑stage trial results for its AI‑discovered drug REC‑4881 in a rare, cancer‑linked condition called familial adenomatous polyposis. The news gives investors something they’ve been waiting on for years: early clinical proof that Recursion’s AI‑driven platform might actually work in real patients. GlobeNewswire+1

8 December 2025

Artificial Intelligence·Biotechnology·NASDAQ:RXRX·Pharmaceuticals

Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

As Wall Street gears up for the opening bell on Monday, December 8, 2025, Merck & Co., Inc. enters the week at a pivotal moment. The Dow component has rallied hard in recent months, but now faces a mix of powerful growth catalysts and fresh legal and financing questions that could shape the next leg of its move.

8 December 2025

NYSE:MRK·Pharmaceuticals·Stock Market

Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

As Wall Street heads into Monday’s session, Eli Lilly and Company sits at the center of several big storylines: Chinese market access for its Alzheimer’s drug, a fresh FDA decision and new data for cancer therapy Jaypirca, price cuts for blockbuster obesity drug Zepbound, and a wave of institutional positioning.

7 December 2025

NYSE:LLY·Pharmaceuticals·Stock Market

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals has had a busy—and volatile—2025. As of the close on Friday, December 5, 2025, VRTX shares finished around $455.48, giving the company a market value in the $115–117 billion range.Stock Titan+3MacroTrends+3StockInvest+3

7 December 2025

Biotechnology·NASDAQ:CRSP·NASDAQ:VRTX·Pharmaceuticals·Stock Market

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Merck & Co., Inc. — the U.S. pharmaceutical company behind blockbuster cancer drug Keytruda and HPV vaccine Gardasil — has just wrapped up a busy early-December news cycle. The company closed a multi‑billion‑dollar debt offering, secured fresh regulatory wins in its cardiopulmonary and animal-health franchises, boosted its dividend, and simultaneously ran into a new patent roadblock for its subcutaneous Keytruda injection in Germany. PR Newswire+4Wikipedia+4Stock Titan+4

7 December 2025

Financial Forecasts·NYSE:MRK·Pharmaceuticals·Stock Market

Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk, the Danish giant behind GLP‑1 blockbusters Wegovy and Ozempic, has gone from Europe’s most valuable listed company to a bruised turnaround story in 2025.

7 December 2025

NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly and Company heads into the final weeks of 2025 as one of the most closely watched stocks on Wall Street – and not just in healthcare. After briefly crossing the $1 trillion market-cap mark in November on the back of explosive demand for its obesity and diabetes drugs, the stock has pulled back slightly but remains near record highs. Reuters+1

6 December 2025

Financial Forecasts·NYSE:LLY·Pharmaceuticals·Stock Market

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Johnson & Johnson stock is ending the first week of December 2025 just below record territory after a powerful year-long rally, driven by a string of earnings beats, major acquisitions in neuroscience and oncology, and fresh clinical data in bladder cancer. At the same time, the company is absorbing huge jury verdicts in talc litigation and preparing to spin off its orthopaedics business, setting up a very different J&J for the second half of the decade. Reuters+4Johnson & Johnson Investor Relations+4Johnson & Johnson Investor Relations+4

6 December 2025

NYSE:JNJ·Pharmaceuticals·Stock Market

Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences stock is trading near the upper end of its 52‑week range as of early December 2025, supported by stronger guidance, big HIV and liver franchises, and a mixed but important year for its oncology pipeline. At the same time, new deals in cell therapy and targeted protein degradation show management leaning into long‑term cancer bets, even at the cost of a bit of near‑term EPS.

6 December 2025

Dividends·NASDAQ:GILD·Pharmaceuticals·Stock Market

Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Eli Lilly and Company remains one of the most closely watched stocks in global markets as investors weigh eye‑popping growth in obesity and diabetes drugs against equally eye‑popping valuations and rising political pressure on drug prices.

5 December 2025

NYSE:LLY·Pharmaceuticals·Stock Market

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK plc is heading into year‑end 2025 on the front foot.

5 December 2025

LSE:GSK·NYSE:GSK·Pharmaceuticals

Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Amgen Inc. has quietly turned into one of 2025’s standout large‑cap healthcare winners. The biotech heavyweight is trading just below fresh 52‑week highs, powered by a clean sweep of earnings beats, a deepening obesity‑drug story around its MariTide program, and full FDA approval for its lung‑cancer therapy Imdelltra. At the same time, investors are grappling with tax and patent overhangs, looming drug price pressure and an increasingly crowded obesity market.

4 December 2025

NASDAQ:AMGN·Pharmaceuticals·Stock Market

Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Regeneron Pharmaceuticals has suddenly become one of the most hotly debated large‑cap biotechs on Wall Street.

4 December 2025

NASDAQ:REGN·Pharmaceuticals

Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

As Tonix Pharmaceuticals transitions from clinical-stage hopeful to commercial biotech on the back of its new fibromyalgia drug Tonmya, Wall Street is split between blockbuster dreams and dilution fears.

4 December 2025

NASDAQ:TNXP·Pharmaceuticals·Stock Market

Eli Lilly (LLY) Stock Today, 4 December 2025: Zepbound Price Cuts, Jaypirca FDA Win and New $1,200–$1,500 Targets

Eli Lilly and Company is trading around $1,030–$1,040 per share on 4 December 2025, down roughly 1% on the session after slipping from about $1,046 in the previous close. Intraday, the stock has been oscillating roughly between $1,022 and $1,051. Intellectia

4 December 2025

NYSE:LLY·Pharmaceuticals·Stock Market

Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

After a sharp rally this week driven by fresh news on its Alzheimer’s drug Cobenfy, an AI-enabled drug discovery milestone and a high‑stakes lawsuit ruling, BMY stock is trading around $50.55, giving the U.S. pharma giant a market capitalization of roughly $104 billion.MarketBeat

4 December 2025

NYSE:BMY·Pharmaceuticals·Stock Market

GSK Stock Near 52‑Week High as FDA Decisions and CEO Transition Loom (LON:GSK, NYSE:GSK)

GSK plc’s share price is pressing against 52‑week highs as 2025 draws to a close, with investors weighing a cluster of near‑term FDA decisions, a major CEO change on 1 January 2026, and a still‑busy share buyback programme.

4 December 2025

LSE:GSK·NYSE:GSK·Pharmaceuticals

Pharmaceuticals 4 December 2025 - 8 December 2025